When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Memo Therapeutics AG raises CHF25m
Latest NewsSwiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage.
microRNA could offer a safe target in atherosclerosis
Latest NewsResearchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls.
Paving the way to internationalisation
Sponsored PublicationsDue to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Navigating the CDMO proposal process
BackgroundWhen businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Cellectis and AstraZeneca in US$2.2bn deal
Latest NewsAstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies.
Alfasigma SpA set to take over Galapagos programme
Latest NewsItalian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos.
Abingworth raises $356m for new CCD fund
Latest NewsRaising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes.
Your Portable Rapid Test Reader
ProductsThe Future of Diagnostic: Portable. Everywhere. Every time. The ESEQuant® Go offers new possibilities for home and self-testing. Take your healthcare into your own hands.
Study links TCM with effects on protein networks
Latest NewsBy mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms.
Challenges in the central lab
BackgroundClinical trials have to be coordinated as a safe process where monitoring, analytics and handling of patient samples is streamlined – even cross oceans. German MLM Medical Labs is quickly establishing itself as an emerging central and specialty lab in the U.S.